Fairmount is a West Conshohocken, Pennsylvania-based venture capital firm investing in promising new therapies from biotechnology and life sciences companies. It backs U.S. therapeutics developers across Series A through Series C financings, including autoimmune, inflammatory, fibrotic and oncology programs, and has acted as a co-lead investor in private biotech rounds. The firm is relevant for life sciences and pharmaceutical companies raising institutional venture capital.